Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells medicines and related pharmaceuticals in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, s… Read more
Tasly Pharmaceutical Group Co Ltd (600535) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 0.055x
Based on the latest financial reports, Tasly Pharmaceutical Group Co Ltd (600535) has a cash flow conversion efficiency ratio of 0.055x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥691.95 Million) by net assets (CN¥12.53 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tasly Pharmaceutical Group Co Ltd - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Tasly Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tasly Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tasly Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hillman Solutions Corp
NASDAQ:HLMN
|
0.021x |
|
Douglas Emmett Inc
NYSE:DEI
|
0.032x |
|
Abbott India Limited
NSE:ABBOTINDIA
|
0.130x |
|
Scatec Solar OL
OL:SCATC
|
0.046x |
|
Deutz AG
XETRA:DEZ
|
0.011x |
|
CGN MINING (VBO.SG)
STU:VBO
|
0.014x |
|
TGS ASA
OTCQX:TGSNF
|
0.091x |
|
Mercari Inc
PINK:MRCIF
|
-0.202x |
Annual Cash Flow Conversion Efficiency for Tasly Pharmaceutical Group Co Ltd (2001–2024)
The table below shows the annual cash flow conversion efficiency of Tasly Pharmaceutical Group Co Ltd from 2001 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥12.11 Billion | CN¥2.01 Billion | 0.166x | -18.05% |
| 2023-12-31 | CN¥12.69 Billion | CN¥2.58 Billion | 0.203x | +12.53% |
| 2022-12-31 | CN¥12.67 Billion | CN¥2.29 Billion | 0.180x | -14.28% |
| 2021-12-31 | CN¥13.31 Billion | CN¥2.80 Billion | 0.210x | +45.47% |
| 2020-12-31 | CN¥12.38 Billion | CN¥1.79 Billion | 0.145x | +2.12% |
| 2019-12-31 | CN¥11.86 Billion | CN¥1.68 Billion | 0.142x | +6.27% |
| 2018-12-31 | CN¥11.21 Billion | CN¥1.49 Billion | 0.133x | +250.33% |
| 2017-12-31 | CN¥8.97 Billion | CN¥-795.62 Million | -0.089x | -163.06% |
| 2016-12-31 | CN¥8.21 Billion | CN¥1.15 Billion | 0.141x | +218.67% |
| 2015-12-31 | CN¥7.71 Billion | CN¥340.00 Million | 0.044x | -63.75% |
| 2014-12-31 | CN¥5.07 Billion | CN¥616.76 Million | 0.122x | +45.65% |
| 2013-12-31 | CN¥4.14 Billion | CN¥346.17 Million | 0.084x | -14.97% |
| 2012-12-31 | CN¥4.21 Billion | CN¥413.31 Million | 0.098x | +174.55% |
| 2011-12-31 | CN¥3.78 Billion | CN¥135.13 Million | 0.036x | -68.97% |
| 2010-12-31 | CN¥3.42 Billion | CN¥395.05 Million | 0.115x | -37.45% |
| 2009-12-31 | CN¥2.17 Billion | CN¥400.38 Million | 0.184x | +48.33% |
| 2008-12-31 | CN¥2.09 Billion | CN¥260.21 Million | 0.124x | +10.81% |
| 2007-12-31 | CN¥1.97 Billion | CN¥221.56 Million | 0.112x | +37.29% |
| 2006-12-31 | CN¥1.72 Billion | CN¥140.56 Million | 0.082x | -40.49% |
| 2005-12-31 | CN¥1.56 Billion | CN¥214.90 Million | 0.137x | -7.14% |
| 2004-12-31 | CN¥1.37 Billion | CN¥203.27 Million | 0.148x | +201.10% |
| 2003-12-31 | CN¥1.20 Billion | CN¥59.01 Million | 0.049x | -76.26% |
| 2002-12-31 | CN¥997.00 Million | CN¥206.22 Million | 0.207x | -38.96% |
| 2001-12-31 | CN¥247.20 Million | CN¥83.77 Million | 0.339x | -- |